The Contemporary Immunotherapies of Pancreatic Cancer
DOI:
https://doi.org/10.62051/2sm0zg44Keywords:
CAR T-cells; GVAX vaccine; Pancreatic cancer; PD-1.Abstract
Pancreatic cancer is a malignant tumor found in the digestive system with hidden onset, rapid progression, poor therapeutic effect and prognosis. In the last few years, immunotherapy has been included in the various solid tumors’ treatment, and pancreatic cancer immunotherapy has gradually attracted attention. Over the past decades, clinical studies have demonstrated some currently typical immunotherapies of pancreatic cancer which has already accepted by the Food and Drug Administration (FDA) which are immune checkpoint inhibitors (ICIs), CAR T-cells and vaccine. Optimistically, results provided by the scientists had described effective outcomes of these immunotherapies in treating this cancer. By combining these new treatments with the traditional, safe therapies, such as surgery or chemotherapy, an increase in patients recover or survival rate has been shown through this combination. However, new therapies mean certain hurdles are existed in these methods due to the identity of “newbies.” The emerging immunotherapeutic treatments for pancreatic patients will be explored, in order to provide more rational treatment recommendations for the patients of pancreatic cancer.
Downloads
References
[1] Halbrook, C. J., Lyssiotis, C. A., Pasca Di Magliano, M., & Maitra, A. (2023). Pancreatic cancer: Advances and challenges. Cell, 186 (8), 1729 – 1754. https: //doi.org/10.1016/j.cell.2023.02.014.
[2] Brouwer, T. P., Vahrmeijer, A. L., & Miranda, N. F. C. C. de. (2021). Immunotherapy for pancreatic cancer: Chasing the light at the end of the tunnel. Cellular Oncology (Dordrecht), 44 (2), 261. https: //doi.org/10.1007/s13402-021-00587-z.
[3] Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022). Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology, 29 (5), 3044 – 3060. https: //doi.org/10.3390/curroncol29050247.
[4] Yoon, J. H., Jung, Y.-J., & Moon, S.-H. (2021). Immunotherapy for pancreatic cancer. World Journal of Clinical Cases, 9 (13), 2969 – 2982. https: //doi.org/10.12998/wjcc.v9.i13.2969.
[5] Mucileanu, A., Chira, R., & Mircea, P. A. (2021). PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies. Medicine and Pharmacy Reports, 94 (4), 402 – 410. https: //doi.org/10.15386/mpr-2116.
[6] Chen, Z., He, Y., Ding, C., Chen, J., Gu, Y., Xiao, M., & Li, Q. (2023). Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study. OncoTargets and Therapy, 16, 923 – 935. https: //doi.org/10.2147/OTT.S427942.
[7] Sandin, L. C., Eriksson, F., Ellmark, P., Loskog, A. S., Tötterman, T. H., & Mangsbo, S. M. (2014). Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. OncoImmunology, 3 (1), e27614. https://doi.org/10.4161/onci.27614.
[8] Leowattana, W., Leowattana, P., & Leowattana, T. (2023). Systemic treatment for advanced pancreatic cancer. World Journal of Gastrointestinal Oncology, 15 (10), 1691 – 1705. https: //doi.org/10.4251/wjgo.v15.i10.1691.
[9] Tran, L. C., Özdemir, B. C., & Berger, M. D. (2023). The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook. Pharmaceuticals, 16 (10), 1411. https: //doi.org/10.3390/ph16101411.
[10] Chen, Y.-J., Abila, B., & Mostafa Kamel, Y. (2023). CAR-T: What Is Next? Cancers, 15 (3), 663. https: //doi.org/10.3390/cancers15030663.
[11] CAR-T cell therapy: A game-changer in cancer treatment and beyond | Clinical and Translational Oncology. (n.d.). Retrieved March 13, 2024, from https: //link.springer.com/article/10.1007/s12094 - 023 – 03368 - 2.
[12] Delm, C., Tano, Z. E., Varghese, A. M., & Adusumilli, P. S. (2017). CAR T-cell Therapy for Pancreatic Cancer. Journal of Surgical Oncology, 116 (1), 63 – 74. https: //doi.org/10.1002/jso.24627.
[13] Mukherji, R., Debnath, D., Hartley, M. L., & Noel, M. S. (2022). The Role of Immunotherapy in Pancreatic Cancer. Current Oncology, 29 (10), 6864 – 6892. https: //doi.org/10.3390/curroncol29100541.
[14] Huang, X., Zhang, G., Tang, T.-Y., Gao, X., & Liang, T.-B. (2022). Personalized pancreatic cancer therapy: From the perspective of mRNA vaccine. Military Medical Research, 9, 53. https: //doi.org/10.1186/s40779-022-00416-w.
[15] Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer Journal, 11 (4), 69. https: //doi.org/10.1038/s41408 - 021 - 00459 - 7.
[16] Czaplicka, A., Lachota, M., Pączek, L., Zagożdżon, R., & Kaleta, B. (2024). Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence. Cells, 13(1), 101. https: //doi.org/10.3390/cells13010101.
[17] Kamolratanakul, S., & Pitisuttithum, P. (2021). Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines, 9(12), Article 12. https: //doi.org/10.3390/vaccines9121413.
[18] Robatel, S., & Schenk, M. (2022). Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment. Cancers, 14 (4), 985. https://doi.org/10.3390/cancers14040985.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
